Clik here to view.
ASCO GU: Dr. Howard Scher on Corticosteroids Use with Enzalutamide in mCRPC
Howard I. Scher, MD, Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Prostate and Urologic Cancers at Memorial Sloan-Kettering Cancer Center, discusses the impact of...
View ArticleClik here to view.
ASCO GU: Dr. Nicholas Vogelzang on Radium-223 in Castration-Resistant...
Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine,...
View ArticleClik here to view.
Dr. Nicholas Vogelzang Shares ASCO-GU Meeting Highlights
The 2013 Genitourinary Cancers Symposium was more about expansion of knowledge than major practice changers. In an interview with The Oncology Report, Dr. Nicholas Vogelzang touches upon this year's...
View ArticleClik here to view.
Pomalidomide Plus Doxil in Multiple Myeloma
James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses a phase I/II study looking at...
View ArticleClik here to view.
Current Brain Tumor Vaccines in Clinical Trials
Behnam Badie, MD, director of City of Hope's Brain Tumor Program, discusses two cancer vaccines currently in clinical trials, and two vaccines in developments.
View ArticleClik here to view.
Dr. Konner Discusses PARP Inhibitors in Ovarian Cancer
Jason A. Konner, MD, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the uncertain path of PARP inhibitors for the treatment of ovarian cancer.
View ArticleClik here to view.
Dr. Nagarsheth Discusses Incidence of Gynecologic Cancers
Dr. Nimesh Nargarseth discusses the drop in cervical cancer rates in the United States. Dr. Nagarsheth has performed extensive research on the mechanisms of cancer prevention, including the hormonal...
View ArticleClik here to view.
ASCO GU: Shorter Duration of ADT Better in Prostate Cancer
Abdenour Nabid, MD, associate professor at Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of...
View ArticleClik here to view.
Information about Kadcyla (T-DM1), a New Breast Cancer Drug
Kadcyla (T-DM1) is an FDA-approved breast cancer drug that targets cancer cells while leaving healthy cells alone. This video provides information about the drug.
View ArticleClik here to view.
The Role of ALK in Non-Small Cell Lung Cancer
Alice Shaw, MD, PhD's lecture at STO Annual Meeting 2010 Review the background of ALK in Non-Small Cell Lung Cancer, the phase 1 trial demonstrating clinical phase 1 data demonstrating clinical...
View ArticleClik here to view.
ASCO 2013: Palbociclib + Letrozole for ER+, HER2- Breast Cancer
Richard Finn, MD, Geffen School of Medicine, on palbociclib (PD-0332991) + letrozole vs placebo + letrozole for postmenopausal women with ER+, HER2- breast cancer who have not received prior...
View ArticleClik here to view.
ASCO 2013: Does Age Affect Care, Outcomes for mPC?
Namrata Vijayvergia, MD, Fox Chase Cancer Center, talks to ChemotherapyAdvisor.com about differences in patterns of care and outcomes of younger vs older patients with metastatic pancreatic cancer (mPC).
View ArticleClik here to view.
ASCO 2013: Dr. Shore on Long-Term Results of the COU-AA-302 Trial
Neal Shore, MD, Director of Carolina Urologic Research Center, talks to ChemotherapyAdvisor.com about long-term safety & efficacy of abiraterone acetate + prednisone in metastatic...
View ArticleClik here to view.
ASCO 2013: Trametinib and Dabrafenib - Two Promising New Melanoma Drugs
Jeffrey Infante, MD, Sarah Cannon Research Institute, discusses the recent May 2013 FDA approvals of trametinib and dabrafenib for melanoma and how these treatments may change oncology practice.
View ArticleClik here to view.
Progress Against Cervical and Ovarian Cancers with Dr. Carolyn Runowicz
Dr. Carolyn Runowicz, Cervical and Ovarian Cancers Specialty Editor for CancerProgress.Net, discusses the advances made in the care and treatment of cervical and ovarian cancers over the last 40...
View ArticleClik here to view.
Dr. Holcombe Discusses Aflibercept for mCRC
Randall F. Holcombe, MD, Associate Director for Clinical Affairs and Director of Gastrointestinal Medical Oncology for the Division of Hematology/Oncology at the Tisch Cancer Institute at Mount Sinai...
View ArticleClik here to view.
The Mechanism of Action of Enzalutamide (Xtandi or MDV3100)
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, discusses the unique mechanism of action for the androgen receptor antagonist...
View ArticleClik here to view.
ASCO 2013: Using Next-Gen Sequencing to Evaluate for Epithelial Cancers
Alan Skarbnik, MD, Fox Chase Cancer Center, discusses how next generation sequencing (NGS) can be applied to evaluate for advanced epithelial cancers.
View ArticleClik here to view.
Dr. Richard Finn on PD 0332991 Plus Letrozole in ER+ Breast Cancer
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, describes results from a phase II study that examined PD 0332991,...
View ArticleClik here to view.
Treating Cancer During Pregnancy
Emerging data on pregnancy and cancer can now help women and their doctors chart a safer course between effective treatment and protecting the developing fetus. Dr. Sarah Temkin discusses the...
View Article
